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A B S T R A C T
Polyamines (putrescine, spermidine and spermine) are aliphatic amines that are produced by the action
of ornithine decarboxylase (ODC) in a rate-limiting and protein kinase C (PKC)-regulated step. Because
high levels of polyamines are found in the synovial ﬂuid of arthritic patients, the aim of the present study
was to identify the role of peripherally produced polyamines in a model of inﬂammatory pain induced by
adjuvant. The subcutaneous injection of Complete Freund’s adjuvant (CFA, 50 mL/paw) caused the
development of mechanical allodynia and edema. Moreover, it increased ODC expression and activity
and PKC activation. Administration of the selective ODC inhibitor DFMO (10 mmol/paw) attenuated the
development of allodynia and edema and decreased ODC activity in both control and CFA-treated
animals. Furthermore, administration of the PKC inhibitor GF109203X (1 nmol/paw) reduced allodynia
and ODC activity in animals injected with CFA. A subcutaneous injection of putrescine (10 mmol/paw),
spermidine (3–10 mmol/paw) or spermine (0.3–3 mmol/paw) into the rat paw also caused mechanical
allodynia and edema. The present results suggest that endogenously synthesized polyamines are
involved in the development of nociception and edema caused by an adjuvant. Moreover, polyamine
production in inﬂammatory sites seems to be related to an increase in ODC activity stimulated by PKC
activation. Thus, controlling polyamine synthesis and action could be a method of controlling
inﬂammatory pain.
 2011 Elsevier Inc.  
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Polyamines (putrescine, spermidine and spermine) are ubiqui-
tous and small aliphatic amines present in almost all cells [1].
Putrescine is formed from the decarboxylation of ornithine by
ornithine decarboxylase (ODC; E.C 4.1.1.17) in a rate-limiting step
in polyamine synthesis [2,3]. Putrescine is converted into
spermidine and spermine by spermidine synthase and spermine
synthase, respectively, which are two aminopropyl transferases
[1,2]. ODC is a protein with a short half-life (10 min-1 h in
mammals), and its activity and expression are highly regulated by
the availability of polyamines and protein kinase C (PKC) [4–6].
Besides being endogenously synthesized, an exogenous supply of
polyamines is provided through dietary intake and intestinal
absorption from bacterial metabolism [7].* Corresponding author at: Universidade Federal de Santa Maria, Departamento
de Quı´mica, Cidade Universita´ria, Avenida Roraima, 1000, Camobi, 97105 900 Santa
Maria, RS, Brazil. Tel.: +55 55 3220 8053; fax: +55 55 3220 8756.
E-mail address: ferreiraj99@gmail.com (J. Ferreira).
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Open access under the Elsevier OA license.Polyamines are involved in several biological processes, including
the control of neuronal excitability and memory improvement and
learning in the central nervous system [1,8]. Previous studies have
shown that a diet deﬁcient in polyamines and supplemented with an
antibiotic (to reduce the level of microﬂora-derived polyamines)
relieves the hyperalgesia induced by incisions, inﬂammation or
neuropathy in rats. This effect seems to be mediated by N-methyl-D-
aspartate receptor (NMDA) in the spinal cord [9,10]. Accordingly,
some studies have shown that spermine administered in the spine
(by the intrathecal route) produces nociceptive behavior in rodents
[11,12]. Apart from their pro-nociceptive action at the spinal cord,
the role of peripheral polyamines in pain is unknown.
Interestingly, increased levels of polyamines are found in
tissues and synovial ﬂuid from patients with osteo-, rheumatoid,
posttraumatic and infectious arthritides [13,14]. Moreover, it has
been demonstrated that the activity and expression of ODC are
increased in colonic tissue from Inﬂammatory Bowel Disease (IBD)
patients [15]. These ﬁndings indicate that endogenously produced
polyamines could play a role in inﬂammatory pain. Therefore, the
present study investigated the role of peripheral, endogenous
polyamines in nociception and edema in the early phase of CFA-
induced inﬂammation.
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2.1. Animals
Experiments were performed on adult male Wistar rats (weight
250–300 g) bred in our animal house. The animals were housed in
a controlled temperature (22  2 8C) with a 12 h light/dark cycle.
They were given standard lab food and water ad libitum. The animals
were habituated to the experimental room for at least 30 min before
the experiments. The experiments were performed in accordance
with current ethical guidelines for the investigation of experimental
pain in conscious animals [16]. The number of animals and the
intensities of the noxious stimuli used were the minimum necessary
to demonstrate the consistent effects of the drug treatments. The
Committee on the Use and Care of Laboratory Animals at our
university approved this study (no. 23081.012331/2009-81).
2.2. Drugs and treatments
The following drugs and chemicals were used in this study:
putrescine, spermidine, spermine, DL-a-diﬂuoromethylornithine-
hydrochloride hydrate (DFMO, 50 ml/paw, an ODC inhibitor), a PKC
inhibitor (GF109203X, 50 ml/paw), phosphate-buffered saline
(PBS), and Complete Freund’s Adjuvant (CFA, 1 mg/ml of heat-
killed Mycobacterium tuberculosis in 85% parafﬁn oil and 15%
mannide monooleate). All drugs and chemicals were obtained
from Sigma (St. Louis, USA). The drug solutions were prepared in
PBS except for GF109203X, which was prepared in 0.1% of dimethyl
sulphoxide (DMSO).
To assess the role of peripheral, endogenous polyamines or PKC
activation in inﬂammatory pain, CFA (50 ml) was administered
subcutaneously (s.c.) under the plantar surface of the right hind
paw, and a separate group of animals received an s.c. injection of
vehicle (PBS). Different groups were also pre-injected s.c. with the
selective ODC inhibitor DFMO (1–10 mmol/paw) or the PKC
inhibitor GF109203X (1 nmol/paw) 1 h before CFA administration.
Higher doses of these drugs were not used because of their
solubility limits.
To determine whether exogenously administered polyamines
were capable of producing nociception or edema, putrescine,
spermine or spermidine (50 ml, 0.003–10 mmol/paw) was also
administered under the plantar surface of the right hind paw s.c.,
and a separate group received an s.c injection of vehicle (PBS).
Higher doses of polyamines were not used because they elicited
spontaneous nociception (observed as hind paw licking, lifting and
shaking/ﬂinching), which made nociception measurements difﬁ-
cult.
The effects of the drugs on nociception and edema were
assessed from 0.5 to 24 h after drug administration. The drug doses
and times of administration were based on pilot studies and
literature [17].
2.3. Nociception assessment
Mechanical allodynia was measured as described previously by
Chaplan et al. [18] and was considered an indicator of nociception.
Rats were placed individually in clear Plexiglas boxes
(9 cm  7 cm  11 cm) on elevated, wire-mesh platforms to access
the ventral surface of the hind paws. The paws were touched with
one in a series of seven von Frey hairs (6–100 g). The von Frey hairs
were applied perpendicular to the plantar surface of the paws with
sufﬁcient force to cause a slight buckling against the paws and
were held for approximately 2 s. The 50% withdrawal threshold
was determined using the up-and-down method of Dixon [19]. In
this paradigm, testing was initiated with the 15-g hair. Stimuli
were always presented consecutively, whether ascending ordescending. Withdrawal thresholds were veriﬁed at several time
points after polyamine or CFA injection (from 0.5 to 24 h) and were
compared with baseline values (before drug administration).
2.4. Edema formation assessment
The edema induced by different agents was considered as the
increase in paw thickness, measured by a digital caliper (Mytutoio,
Japan), as described previously by Milano et al. [20]. Paw
thicknesses were veriﬁed at several time points after polyamine
or CFA injection (0.5–24 h) and compared to baseline values
(before drug administration).
2.5. ODC activity
After behavioral observation, paw-skin samples proximal to the
point of injection were collected to perform ODC activity analysis
according to Tabib [21] with minor modiﬁcations. The samples
were homogenized in buffer (10 mM Tris–HCl, pH 7.5) containing
2.5 mM of DL-dithiothreitol (DTT) and 0.1 mM of ethylenediami-
netetraacetic acid (EDTA). Following a 10-min incubation at 4 8C,
the homogenates were centrifuged at 35,000  g for 45 min at 4 8C,
and the supernatants were collected. The protein in the super-
natants was measured using the Bradford [22] method. To perform
these reactions, 200 ml (0.5 mg/ml of protein) of the supernatants
was added to assay buffer (1 M Tris–HCl (pH 7.5), 250 mM of DTT,
2 mM of pyridoxal phosphate, 20 mM of L-ornithine, and 0.1 m of
Ci/ml L-[1-14C]-ornithine), and the mixtures were incubated at
37 8C for 30 min in capped-glass tubes. A ﬁlter-paper humidiﬁer
was attached to the top of each tube in 0.25 ml of 1 M hyamine
hydroxide. Sulphuric acid (250 mL, 5 M) was added to the
reactions, and the mixtures were incubated for 30 min at 37 8C.
The ﬁlter papers were then collected to measure the 14CO2 released
from [14C]-ornithine. ODC activity was expressed as 14CO2%,
compared with the control group (PBS-treated paws). The mean
activity of ODC in the control group was 7.1  0.7 pmol/min/mg
protein.
2.6. ODC expression
We also performed Western blot analysis to verify the
expression of ODC protein in the paw-skin samples. The assay
was performed as described previously [17] with minor modiﬁca-
tions. The paw tissues were homogenized in 300 ml of ice-cold
buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 2 mM MgCl2, 1 mM
EDTA, 1 mM NaF, 10 mg/ml aprotinin, 10 mM b-glycerolpho-
sphate, 1 mM phenylmethanesulphonyl ﬂuoride (PMSF), 1 mM
DTT and 2 mM of sodium orthovanadate). After centrifugation
(13,000  g for 30 min at 4 8C), the supernatants containing the
cytosolic fraction were collected. The protein contents were
determined by the method of Bradford [22] using bovine serum
albumin (BSA) as the standard. Protein (70 mg) as mixed in loading
buffer (200 mM Tris, 10% glycerol, 2% SDS, 2.75 mM b-mercap-
toethanol and 0.04% bromophenol blue) and boiled for 5 min.
Proteins were separated in 12% sodium dodecyl sulphate-
polyacrylamide (SDS-PAGE) gels and transferred to polyvinylidene
diﬂuoride (PVDF) membranes according to the manufacturer’s
instructions (PerkinElmer, USA). Proteins were stained on the PVDF
membrane with a solution of 0.5% actin and 1% glacial acetic acid in
water, and this served as the loading control [23]. The membranes
were then dried, scanned and quantiﬁed with the PC version of
Scion Image. The membranes were washed, blocked with 1% BSA in
TBS-T (0.05% Tween 20 in Tris-borate saline) and incubated for
10 min with diluted (1:150), primary antibodies against ODC
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membranes
were processed using a SNAP i.d. system (Millipore, USA). Blots
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alkaline phosphatase-coupled secondary antibody (1:3000) for
10 min. The protein bands were visualized with the 5-bromo-4-
chloro-3-indolyl phosphate/p-nitro blue tetrazolium system
(BCIP/NBT). The membranes were dried, scanned and quantiﬁed
again, and the ODC Western blot showed a faint background that
was corrected in the image analysis.
2.7. PKC activation
Phospho-PKC is the catalytically active form of PKC [24]. We
performed Western blot analysis on the paw-skin samples to
observe possible changes in PKC activation. This was veriﬁed as an
increase in the detection of the phosphorylated form of PKC and
the ratio between the phosphorylated and total forms of PKC after
drug administrations. The method was similar to that described
previously in Kassuya et al. [25] with some modiﬁcations. The paw
tissues were homogenized in a lysis buffer containing 50 mM
HEPES (pH 7.9), 1 M KCL, 1 M MgCl2, 0.1 M EDTA, 0.1 M NaF,
10 mg/ml aprotinin, 1 M b-glycerolphosphate, 200 mM phenyl-
methanesulphonyl ﬂuoride, 1 M DTT and 0.1 M of sodium
orthovanadate. After centrifugation (13,000  g for 30 min at
4 8C), the supernatants containing the cytosolic fraction were
collected. For PKC activation, the samples (70 mg protein) were
incubated for 10 min with 1:150 dilutions of primary antibodies to
PKC and phospho-PKC (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). The protein bands were visualized with a BCIP/NBT system.
The membranes were dried, scanned and quantiﬁed with the PC
version of Scion Image. The PKC Western blot showed a faint
background that was corrected in the image analysis.Fig. 1. Time-courses (A and C) and dose–response curves (B and D) for the ODC inhibitor D
by CFA. The dose–response curves for allodynia or edema were assessed at 4 or 6 h, re
##P < 0.01 and #P < 0.05 compared to baseline (B) values. *P < 0.05 and **P < 0.01 compa2.8. Statistical analyses
The results are expressed as the mean  SEM. A Student’s t-
test and one-way or two-way analysis of variance (ANOVA) were
used to analyze the statistical signiﬁcance between groups
followed by Bonferroni’s or Student–Newman–Keuls’ (SNK) post
hoc tests. The level of signiﬁcance was set at P < 0.05, and F values
demonstrated treatment versus time interactions. The values of
ED50 (the dose of drug necessary to produce 50% of the nociceptive
response relative to the maximum effect) are reported as the
geometric means and their respective 95% conﬁdence limits
(GraphPad Software 5.0, Graph Pad, USA). The ED50, Emax (maximal
effect) and Imax (maximal inhibition) were calculated based on the
responses of the control group. To meet ANOVA assumptions,
mechanical allodynia data were subjected to Log transformation
before statistical analysis.
3. Results
3.1. Effects of endogenous polyamine production on mechanical
allodynia and paw edema in rats with adjuvant inﬂammation
To investigate the role of endogenous polyamines in mechani-
cal allodynia and edema, we tested the effect of the selective ODC
inhibitor DFMO in CFA-induced inﬂammation. We observed a
decreased mechanical threshold (mechanical allodynia) and
increased paw thickness (paw edema) from 0.5 to 24 h after s.c.
administration of CFA (50 ml/paw), compared with baseline values
(Fig. 1A and C). Pre-treatment with s.c. DFMO (10 mmol/paw)
reduced the mechanical allodynia induced by CFA signiﬁcantlyFMO’s effects on mechanical allodynia (A and B) and paw edema (C and D) induced
spectively, after CFA injection. Data represented as mean  SEM from 9 to 12 rats.
red to the vehicle group (one-way ANOVA followed by SNK test).
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(1,23) = 4.136, P < 0.0008]. The maximal inhibition (Imax) ob-
served 4 h after administration was 29  5% with a dose of
10 mmol/paw (Fig. 1A and B). Moreover, we also observed that DFMO
attenuated the edema formation induced by CFA injection after 4 h [F
(1,23) = 214.9, P < 0.0001] and 6 h [F (1,23) = 6.440, P < 0.0001]. The
most pronounced effect was observed 6 h after CFA treatment when
the Imax was 28  4%, which was obtained with a dose of 10 mmol/
paw (Fig. 1C and D). We also observed that CFA-induced thermal
hyperalgesia was not altered by DFMO treatment (results not
shown).Fig. 2. Time-courses (A, C and E) and dose–response curves (B, D and F) for the induction o
(SPD) or spermine (SPM). Each data point represents the mean  SEM from 7 rats for A and
(PBS) group (one-way ANOVA followed by SNK test).3.2. Effects of exogenously administered polyamines on mechanical
allodynia and edema in non-arthritic rats
After inhibiting endogenous polyamine synthesis and reducing
inﬂammatory pain in arthritic rats, we tested the ability of
polyamines to induce nociception and edema in non-arthritic rats.
Peripheral s.c. administration of putrescine (10 mmol/paw),
spermidine (10 mmol/paw) or spermine (1 mmol/paw) caused
mechanical allodynia starting at 0.5, 1 and 0.5 h, respectively, after
injection and persisted for 6, 4 and 4 h, respectively (Fig. 2A–C). The
peak effects for mechanical allodynia were observed at 2, 1 and 2 hf mechanical allodynia in rats by peripheral injection of putrescine (PUT), spermidine
 B, 5 rats for C and D and 9 rats for E and F. *P < 0.05 and **P < 0.01 compared to vehicle
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Respective maximal effects (Emaxs) were 39  5%, 65  10% and
43  9% of the mechanical threshold, compared with the control
group (Fig. 2). Because the allodynias induced by putrescine,
spermidine and spermine were not dose-dependent (Fig. 2B, D and
F), the ED50 values were not calculated for these polyamines.
Similar to nociception, s.c. administration of putrescine
(10 mmol/paw), spermidine (10 mmol/paw) or spermine
(1 mmol/paw) also induced paw edema starting 0.5 h after
injection and persisted for 6 h for all polyamines (Fig. 3A–C).
The peak effect for edema was also observed 30 min after injection
for all polyamines, and Emaxs of 31  3%, 49  3% and 29  3% of the
paw thickness increase were observed, compared with the control
group, for putrescine, spermidine or spermine, respectively (Fig. 3).
Moreover, similar to nociception, edema induced by these com-Fig. 3. Time-courses (A, C and E) and dose–response curves (B, D and F) for the induction o
or spermine (SPM). Each data point represents the mean  SEM from 7 rats for A and B, 5 r
vehicle (PBS) group (one-way ANOVA followed by SNK test).pounds (Fig. 3D and F) was not dose-dependent, and therefore, ED50
values were not calculated.
3.3. ODC expression and activity in inﬂamed tissue from rats with
adjuvant inﬂammation
Because we observed that inhibiting polyamine synthesis
reduced inﬂammatory pain, we directly evaluated ODC activity
after CFA injection. When compared with vehicle-treated rats, CFA
signiﬁcantly increased the ODC activity at 2 h (24  2%), 4 h
(38  5%) and 6 h (50  15%) after injection (Fig. 4A). Moreover, we
veriﬁed that the dose of DFMO (10 mmol/paw) that reduced CFA-
induced nociception and edema was also effective in fully preventing
the increase in ODC activity observed 4 h after CFA administration
(Fig. 4B). DFMO (10 mmol/paw) pre-treatment also reduced thef paw edema in rats by the peripheral injection of putrescine (PUT), spermidine (SPD)
ats for C and D and 9 rats for E and F. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to
Fig. 4. (A) Effect of CFA on ODC activity in injected paw tissue. (B) Effect of DFMO
pre-treatment or its vehicle on ODC activity in rats injected with CFA or PBS. Data
expressed as the mean  SEM from 6 rats. *P < 0.05 and **P < 0.01 compared to the
PBS group. #P < 0.05 compared to vehicle-treated groups injected with CFA or PBS
(two-way ANOVA followed by Bonferroni’s test).
Fig. 5. Effect of CFA on ODC protein expression in injected paw tissue. (A) Western
blot analysis of ODC expression in paw samples 2, 4 and 6 h after injection of CFA or
PBS. To demonstrate equal loading, a representative actin-stained protein band is
shown. (B) Quantiﬁcation of ODC protein expression. Data expressed as the
mean  SEM from 4 to 6 rats. *P < 0.05 compared to PBS control (one-way ANOVA
followed by SNK test).
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(Fig. 4B).
Because ODC activity could be altered by CFA, we also observed
the effect of adjuvant on ODC expression. We observed that CFA
injection increased ODC protein expression 2, 4 and 6 h after CFA
injection, compared with that in the PBS group (Fig. 5A and B).
3.4. Effect of PKC activation on allodynia, edema and increased ODC
activity induced by CFA injection
We ﬁrst measured changes in PKC activation in the CFA-
induced inﬂammatory state. CFA signiﬁcantly increased the
detection of the ratio between phosphorylated and total forms
of PKC 4 h after its injection, and decreased the phospho-PKC form
of PKCs after 6 h, without changes in the total form of PKC (Fig. 6A–
E). Moreover, we assessed the effects of GF109203X, a selective
PKC inhibitor, on mechanical allodynia, paw edema and increased
ODC activity induced by CFA. The administration of GF109203X
(1 nmol/paw) reduced the mechanical allodynia but not the paw
edema induced by CFA in 4 h [F (1,5) = 6.208, P < 0.05], with an
inhibition of 74  4%, compared with the vehicle group (Fig. 7A and
B). GF109203X also prevented an increase in ODC activity after 4 h the
CFA injection without changing ODC activity in PBS-treated animals
(Fig. 8).
4. Discussion
Polyamines are ubiquitous and aliphatic amines involved in
several biological processes. Here, we show that peripheral
polyamines are related to the induction of inﬂammatory pain,
because ODC inhibition reduced endogenous polyamine produc-
tion and decreased the nociception and edema related to
inﬂammatory processes. Moreover, injection of exogenous poly-
amines caused nociception and edema, and the activity and
expression of ODC were increased in the inﬂammatory tissue. We
also demonstrated that the action of PKC is related to the increased
activity of ODC and nociception and edema production.
It is known that CFA produces chronic inﬂammation in rodents
[13]. In the present study, we showed that subcutaneous
administration of the ODC inhibitor DFMO had a long-lasting,
antinociceptive effect on the mechanical allodynia induced by CFA
in rats. Our results are in accordance with previous ﬁndings that
showed that a polyamine-deﬁcient diet relieves the mechanical
hyperalgesia induced by inﬂammation in rats [9,10]. Thus, both the
restriction of polyamine ingestion and the inhibition of polyamine
synthesis could be strategies for improving the treatment of
inﬂammatory pain. Furthermore, we also observed that DFMO
treatment did not alter CFA-induced thermal hyperalgesia. Since it
has been described that mechanical and thermal stimuli are
detected by different afferent ﬁbers [26], the target to the
nociceptive action of polyamines seems to be restricted to the
subset of ﬁbers that mediates mechanical pain.
Several clinical studies have demonstrated a critical role for
polyamines in arthritis. Increased levels of polyamines are found in
synovial ﬂuid, synovial membrane, urine and lymphocytes of
arthritic patients and seem to be related to the activity and
progression of the disease [13,27,28]. Furthermore, the anti-
arthritic effect of methotrexate seems to be associated with its
ability to reduce polyamine levels [14,28]. There are also increased
levels of polyamines in the paws of rats injected with CFA [29].
Conﬁrming the idea that peripheral polyamines function as pro-
nociceptive agents, we showed that exogenous polyamines
injected into the rat paw induced mechanical allodynia. It has
been previously demonstrated that intrathecally injected sper-
mine produced nociceptive behaviors in rodents [11,12]. Thus,
similar to the spinal cord injections, peripheral polyamines
Fig. 6. Effect of CFA on PKC activation assessed by the expression of the total and
phosphorylated forms of PKC and the ratio of these forms. (A) Western blot analysis
of the total form and (C) analysis of the phosphorylated form of PKC expression in
paw samples 2, 4 and 6 h after the injection of CFA or PBS. To demonstrate equal
loading, a representative actin-stained protein band is show. (B) Quantiﬁcations of
Fig. 7. Effect of pre-treatment with GF109203X on mechanical allodynia (A) and
paw edema (B) assessed 4 h after CFA administration. Data expressed as the
mean  SEM from 5 rats. **P < 0.01 compared to vehicle and PBS group. ##P < 0.01
compared to vehicle and CFA group (one-way ANOVA).
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spermine-solution concentrations injected (0.3–10 mM to gener-
ate doses of 0.03–1 mmol/paw) into the rat paw are in the same
range of the spermine concentration in synovial tissues from
arthritic patients (about 0.3 mM) and in paw tissue of CFA-injected
rats (about 400 mM) [13,29]. This suggests that the doses of
polyamines used in our study to cause nociception may be found in
inﬂamed tissues.
We found that the potency, but not the efﬁcacy, of polyamines
to induce allodynia is dependent on their charge because spermine,
which is the most charged polyamine, was more potent than
putrescine in producing nociception. It has been described that
some polyamine actions, such as interacting with the ion channel,
are charge-dependent [30]. The exact target that peripheral
polyamines interact with to produce nociception is still unknown;
however, in the spinal cord, the glutamate NMDA receptor is an
important target [11,12]. There are also NMDA receptors in the
peripheral terminals of nociceptors that, when stimulated by
glutamate, induce nociception in rodents [31]. Moreover, poly-
amines may also stimulate the vanilloid TRPV1 receptor, which
could trigger nociceptor activation [30]. However, the exact
mechanisms responsible for the nociceptive effect induced by
polyamines needs to be determined. Besides NMDA and TRPV1
receptors, polyamines may interact with different afﬁnities inthe total form, (D) phosphorylated form and (E) the ratio of the total and
phosphorylated forms of PKC. Data expressed as the mean  SEM from 4 rats.
*P < 0.05 compared to PBS-injected rats (Student’s t-test).
Fig. 8. Effect of GF109203X on ODC activity in CFA or PBS-treated rats. Data
expressed as the mean  SEM from 4 rats. **P < 0.01 compared to vehicle and PBS
group. #P < 0.01 compared to vehicle and CFA group (one-way ANOVA).
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negatively the nociceptive process. This plethora of targets may
explain why we did not detect dose–response relationships for
nociceptive and edematogenic actions of polyamines.
During inﬂammatory processes, events, such as edema and
enhanced nociception, may occur. Similar to the nociceptive
behavior, polyamine injection induced edema, and spermine
remained the most potent polyamine tested (it produced edema
with lower doses than the other polyamines), while spermidine
was the most efﬁcacious polyamine (it induced a greater edema –
Emax value – when compared with the other polyamines). In
addition, our study also showed that DFMO treatment reduced the
paw edema induced by CFA. In accordance with our ﬁndings, it has
been reported that DFMO treatment reduces edema produced by
lung or brain injury [33,34].
We also observed that CFA increased ODC activity and
expression, compared to that in the control group. Moreover,
DFMO, administered at a dose that possessed anti-allodynic and
anti-edematogenic effects, was able to reduce ODC activity in CFA-
treated and control animals. ODC, the rate-limiting enzyme in
polyamine biosynthesis, is very highly regulated, and alterations in
its activity are through changes in the amount of ODC protein,
which turns over very rapidly [6]. In our study, CFA increased the
amount of ODC protein and the activity of ODC 2–6 h after its
injection. Thus, the increased ODC activity observed after CFA
injection is, at least in part, related to the increase in protein.
ODC activity varies in response to many stimuli. PKC activity
inﬂuences polyamine metabolism through a critical regulation of
ODC activation, at the levels of transcription, translocation and
protein turnover [6,35]. For example, ODC activity may be
decreased by PKC depletion and increased by PKC over-expression
[5]. Similar to what is found in the spinal cord of CFA-treated
rodents [36], we detected, for the ﬁrst time, an increase in PKC
activation, which was detected as an increase in the ratio of
phosphorylated and total forms of PKC 4 h after CFA administra-
tion. This effect was not an unexpected ﬁnding, because an
adjuvant injection increases the local level of several pro-
nociceptive mediators that stimulate PKC, such as cytokines and
the nerve growth factor [37,38]. We also detected a decrease in the
phosphorylated form of PKC 6 h after CFA was given. This may be
explained by the fact that phosphorylation of PKC renders it
sensitive to degradation [24].
GF109203X, an inhibitor of PKC, signiﬁcantly inhibited the ODC
activity and mechanical allodynia increases observed in adjuvant-
injected animals without altering ODC activity in control rats. This
indicates that PKC is involved in polyamine-related inﬂammatorynociception, Furthermore, because the PKC inhibitor was more
effective than the ODC inhibitor in reducing the mechanical
allodynia caused by CFA, PKC seems to have other pro-nociceptive
targets besides ODC. Several ion channels and receptors can be
modulated by PKC in sensory neurons to induce pain [38]. PKC
inhibition was not able to alter edema starting 4 h after CFA
administration. This agrees with a previous study, which
demonstrated that PKC is not involved in the ﬁrst phase (1–9
days) of CFA-induced edema in rats [39].
Taken together, these results suggest that endogenously
synthesized polyamines are involved in the development of
nociception caused by an adjuvant. Moreover, polyamine produc-
tion in inﬂammatory sites seems to be related to an increase in ODC
activity stimulated by PKC activation. Thus, controlling polyamine
synthesis and action could be a potential method for controlling
inﬂammatory pain.
Acknowledgements
This study was supported by the Conselho Nacional de
Desenvolvimento Cientı´ﬁco (CNPq), Coordenac¸a˜o de Aper-
feic¸oamento de Pessoal de Nı´vel Superior (CAPES), Instituto do
Mileˆnio, Instituto Nacional de Cieˆncia e Tecnologia (INCT) em
Medicina Molecular. We thank CNPq and CAPES for their
fellowship support.
References
[1] Kusano T, Berberich T, Tateda C, Takahashi Y. Polyamines: essential factors for
growth and survival. Planta 2008;228:367–81.
[2] Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer
and other hyperproliferative diseases. Nat Rev Drug Discov 2007;6:373–90.
[3] Schipper RG, Verhosfstad AAJ. Distribution patterns of ornithine decarboxylase
in cells and tissues: facts, problems, and postulates. J Histochem Cytochem
2002;50:1143–60.
[4] Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism.
Biochem J 2003;376:1–14.
[5] Zhao YJ, Zhang WH, Xu CQ, Li HZ, Wang LN, Li H, et al. Involvement of the
ornithine decarboxylase/polyamine system in precondition-induced cardio-
protection through an interaction with PKC in rat hearts. Mol Cell Biochem
2009;332:135–44.
[6] Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem 2006;281:14529–
32.
[7] Larque´ E, Sabater-Molina M, Zamora S. Biological signiﬁcance of dietary
polyamines. Nutrition 2007;23:87–95.
[8] Rubin MA, Stiegemeier AJ, Volkweis MA, Oliveira DM, Fenili AC, Rafael LB, et al.
Intra-amygdala spermine administration improves inhibitory avoidance per-
formance in rats. Eur J Pharmacol 2001;423:35–9.
[9] Estebe JP, Legay F, Gentili M, Wodey E, Leduc C, Ecoffey C, et al. An evaluation of
a polyamine-deﬁcient diet for the treatment of inﬂammatory pain. Anesth
Analg 2006;102:1781–8.
[10] Rivat C, Richebe´ P, Laboureyras E, Laulin JP, Havouis R, Noble F, et al. Polyamine
deﬁcient diet to relieve pain hypersensitivity. Pain 2008;137:125–37.
[11] Kolhekar R, Meller ST, Gebhart GF. N-methyl-D-aspartate receptor-mediated
changes in thermal nociception: allosteric modulation at glycine and poly-
amine recognition sites. J Neurosci 1994;63:925–36.
[12] Tan-No K, Taira A, Wako K, Niijima F, Nakagawasai O, Tadano T, et al.
Intrathecally administered spermine produces the scratching, biting and
licking behaviour in mice. Pain 2000;86:55–61.
[13] Yukioka K, Wakitani S, Yukioka M, Furumitsu Y, Shichikawa K, Ochi T, et al.
Polyamine levels in synovial tissues and synovial ﬂuids of patients with
rheumatoid arthritis. J Rheumtol 1992;19:689–92.
[14] Nesher G, Osborn TG, Moore TL. In vitro effects of methotrexate on polyamine
levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol
1996;14:395–9.
[15] Pillai RB, Tolia V, Rabah R, Simpson PM, Vijesurier R, Lin CH. Increased colonic
ornithine decarboxylase activity in inﬂammatory bowel disease in children.
Dig Dis Sci 1999;44:1565–70.
[16] Zimmermann M. Ethical guidelines for investigations of experimental pain in
conscious animals. Pain 1983;16:109–10.
[17] Ferreira J, Triche´s KM, Medeiros R, Calixto JB. Mechanisms involved in the
nociception produced peripheral protein kinase C activation in mice. Pain
2005;117:171–81.
[18] Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment
of tactile allodynia in the rat paw. J Neurosci Meth 1994;53:55–63.
[19] Dixon WJ. Efﬁcient analysis of experimental observations. Annu Rev Pharma-
col Toxicol 1980;20:441–62.
M.A. Silva et al. / Biochemical Pharmacology 82 (2011) 269–277 277[20] Milano J, Rossato MF, Oliveira SM, Drewes C, Machado P, Beck P. Antinoci-
ceptive action of 4-methyl-5-triﬂuomethyl-5-hydroxy-4,5-dihydro-1 H-pyr-
azole methyl ester in models of inﬂammatory pain in mice. Life Sci
2008;83:739–46.
[21] Tabib A. Determination of ornithine decarboxylase activity using [14CO2]
ornithine. In: Morgan DML, editor. Polyamines Protocols Methods in Molec-
ular Biology, vol. 74. 1998. p. 33–40.
[22] Bradford MM. A rapid and sensitive method for the quantiﬁcation of micro-
gram quantities of protein utilizing the principle of protein–dye binding. Anal
Biochem 1976;72:248–54.
[23] Calvo IR, Oco´n B, Moya PM, Sua´rez MD, Zarzuelo A, Augustin OM, et al.
Reversible Ponceau staining as a loading control alternative to action in
Western blots. Anal Biochem 2010;401:318–20.
[24] Ohno S, Konno Y, Akita Y. A point mutation at the putative ATP-binding site of
protein kinase C alpha abolishes the kinase activity and renders it down-
regulation-insensitive. A molecular link between autophosphorylation and
down-regulation. J Biol Chem 1990;265:6296–300.
[25] Kassuya CAL, Ferreira J, Claudino RF, Calixto JB. Intraplantar PGE2 causes
nociceptive behaviour and mechanical allodynia: the role of prostanoid E
receptors and protein kinases. Br J Pharmacol 2007;150:727–37.
[26] Cavanaugh DJ, Lee H, Lo L, Shields SD, Zylka MJ, Basbaum AI. Distinct subsets of
unmyelinated primary sensory ﬁbers mediate behavioral responses to noxious
thermal and mechanical stimuli. Proc Natl Acad Sci U S A 2009;106:9075–80.
[27] Furumitsu Y, Yukioka K, Kojima A. Levels of urinary polyamines in patients
with rheumatoid arthritis. J Rheumatol 1993;20:1661–5.
[28] Nesher G, Osborn TG, Moore TL. Effect of treatment with methotrexate,
hydroxychloroquine, and prednisone on lymphocyte polyamine levels in
rheumatoid arthritis: correlation with the clinical response and rheumatoid
factor synthesis. Clin Exp Rheumatol 1997;15:343–7.[29] Chakradhar LV, Naik SR. Polyamines in inﬂammation and their modulation by
conventional anti-inﬂammatory drugs. Indian J Exp Biol 2007;45:649–53.
[30] Ahern GP, Wang X, Miyares RL. Polyamines are potent ligands for the capsaicin
receptor TRPV1. J Biol Chem 2006;281:8991–5.
[31] Carlton SM. Peripheral excitatory amino acids. Curr Opin Pharmacol
2001;1:52–6.
[32] Bowie D, Mayer ML. Inward rectiﬁcation of both AMPA and Kainate subtype
glutamate receptors generated by polyamines-mediated ion channel block.
Neuron 1995;15:453–62.
[33] Bas¸ kaya MK, Rao AM, Puckett L. Effect of diﬂuoromethylornithine treatment
on regional ornithine decarboxylase activity and edema formation after
experimental brain injury. J Neurotrauma 1996;13:85–92.
[34] Olson JW, Atkinson JE, Hacker AD. Suppression of polyamine biosynthesis
prevents monocrotaline-induced pulmonary edema and arterial medial thick-
ening. Toxicol Appl Pharmacol 1985;81:91–9.
[35] Shantz LM, Levin VA. Regulation of ornithine decarboxylase during oncogenic
transformation: mechanisms and therapeutic potential. Amino acids
2007;33:213–23.
[36] Cheng HT, Suzuki M, Hegarty DM. Inﬂammatory pain-induced signaling
events following a conditional deletion of the N-methyl-D-aspartate receptor
in spinal cord dorsal horn. Neuroscience 2008;155:948–58.
[37] Woolf CJ, Allchorne A, Saﬁeh-Garabedian B. Cytokines, nerve growth factor
and inﬂammatory hyperalgesia: the contribution of tumour necrosis factor
alpha. Br J Pharmacol 1997;121:417–24.
[38] Vela´zquez KT, Mohammad H, Sweitzer SM. Protein kinase C in pain: involve-
ment of multiple isoforms. Pharmacol Res 2007;55:578–89.
[39] Birchall AM, Bishop J, Bradshaw D. Ro 32-0432, a selective and orally active
inhibitor of protein kinase C prevents T-cell activation. J Pharmacol Exp Ther
1994;268:922–9.
